Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Takayuki YoshinoEiji OkiToshihiro MisumiMasahito KotakaDai ManakaTetsuya EtoJunichi HasegawaAkinori TakaganeMasato NakamuraTakeshi KatoYoshinori MunemotoFumitaka NakamuraHiroyuki BandoHiroki TaniguchiYasuhiro SakamotoManabu ShiozawaMasayasu NishiTetsuya HoriuchiHisakazu YamagishiJunichi SakamotoTsunekazu MizushimaAtsushi OhtsuMasaki MoriPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
In Asian patients, shortening adjuvant therapy duration from 6 to 3 months did not compromise efficacy and reduced the rate of long-lasting peripheral sensory neuropathy. In this setting, 3 months of CAPOX therapy is an appropriate adjuvant treatment option.
Keyphrases
- phase iii
- open label
- clinical trial
- double blind
- phase ii
- placebo controlled
- end stage renal disease
- early stage
- chronic kidney disease
- newly diagnosed
- ejection fraction
- study protocol
- prognostic factors
- stem cells
- peritoneal dialysis
- randomized controlled trial
- bone marrow
- patient reported outcomes
- mesenchymal stem cells
- cell therapy
- patient reported